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Tuberculosis, an ancient disease of mankind, remains one of the major infectious causes of human
death.We examine newly discovered facets of tuberculosis pathogenesis and explore the evolution
of its causative organism Mycobacterium tuberculosis from soil dweller to human pathogen.
M. tuberculosis has coevolved with the human host to evade and exploit host macrophages and
other immune cells in multiple ways. Though the host can often clear infection, the organism can
cause transmissible disease in enough individuals to sustain itself. Tuberculosis is a near-perfect
paradigm of a host-pathogen relationship, and that may be the challenge to the development of
new therapies for its eradication.Introduction
Tuberculosis (TB) has afflicted humans for about 70,000 years
and continues to take a huge toll on human life and health,
with 8.6 and 1.3 million cases and deaths, respectively, in 2013
(Zumla et al., 2013; Comas et al., 2013). TB’s timelessness in
the face of significant human lifestyle changes over the millennia
and the advances of modern medicine over the last century
bespeak the agility and toughness of its causative pathogen
Mycobacterium tuberculosis. M. tuberculosis may be the para-
digm for human host-pathogen adaptation.
TB’s notoriety as one of the great bacterial terrors of humanity
alongside plague, typhus, cholera, typhoid, and diphtheria has
led to descriptors such as the ‘‘great white plague’’ and ‘‘the
captain of all those men of death.’’ When compared to other ma-
jor bacterial diseases, there are some interesting and potentially
informative aspects of TB’s pathogenesis. Human infection and
disease is essential for the transmission and therefore the evolu-
tionary survival of M. tuberculosis. This is in contrast to plague,
which, despite its enormous impact on human history, is a
zoonosis in which human disease is essentially an accident
with no bearing on the pathogen’s subsequent survival. The
same could be said for many commensal pathogens, e.g., the
pneumococcus, meningococcus, or the flesh-eating strepto-
cocci, in which human disease, though terrifying, is of marginal
benefit to the long-term survival of the pathogen. Despite the
inextricable connection between disease and transmission and
thereby its survival,M. tuberculosis appears to lack the classical
virulence factors that are the badges of honor of many of these
pathogens. These include capsules to avoid phagocytosis, pili,
or other adhesins for adherence to host tissues; flagella for
motility; and enzymes and toxins to poison host cells. How
doesM. tuberculosis produce the disease so devastating to hu-
mans and so vital to the pathogen? The classical virulence fac-
tors of the mucosal commensal pathogens, many of which
reside in the nasopharynx, are really colonization factors that,in the right host, run amok to cause a disease that is of question-
able benefit to the pathogens’ evolutionary survival. These
factors probably give the microbe a selective colonization
advantage on mucosal surfaces, where bacterial competition is
rife. Not surprisingly, vaccines against individual virulence fac-
tors—be it a capsule of the pneumococcus or a toxin—some-
times eradicate colonization along with disease. As an example,
the diphtheria toxin that has been responsible for countless
million deaths in the past is likely a colonization factor that allows
Corynebacterium diphtheria to compete effectively with other
mucosal bacteria to establish a privileged niche in the tonsils.
The diphtheria vaccine that is directed against this single toxin
has wiped out colonization together with disease. These re-
present the more recently evolved ‘‘crowd’’ diseases that
emerged in the neolithic age associated with the development
of agriculture and the domestication of animals. In contrast,
M. tuberculosis is an ancient companion of man since before
the neolithic age and its associated crowding (Comas et al.,
2013), making TB a ‘‘heritage’’ disease for much of its history.
We argue thatM. tuberculosis andmany of the other host-adapt-
ed mycobacteria have evolved a different strategy for insuring
persistence in the host—they have honed their lifestyle to
obviate the need for virulence (ne´e colonization) factors like
toxins and enzymes that break down anatomic barriers to
outcompete other pathogens. Instead they use host macro-
phages to traverse host mucosal barriers to sterile sites deep
in the body. As we see it, M. tuberculosis’ dirty little secret is to
be hydrophobic and to ‘‘fly’’ more efficiently in a tiny droplet to
bypass the innate immune system. Rather than jostling with
other pesky microbes, M. tuberculosis can deal just with its
host, and we suggest that host immune evasion, modulation,
and exploitation are the trump cards of the pathogenic myco-
bacteria. This recognition of M. tuberculosis’ tactics brings a
new understanding of host and pathogen biology that can poten-
tially be parlayed into new therapies and interventions.Cell 159, December 18, 2014 ª2014 Elsevier Inc. 1497
This Review will examine key new discoveries about TB path-
ogenesis against a backdrop of the natural history of infection
and disease and its difficult treatment. We note that TB patho-
genesis was last reviewed in Cell in 2001 (Glickman and Jacobs,
2001), a time that marked the derivation of a basic molecular ge-
netic toolkit for M. tuberculosis and the postgenomic era of TB
research being ushered in following the elucidation of its genome
sequence (Cole et al., 1998). The earlier Cell Review highlighted
the problem of lengthy drug treatment as a factor that made
global eradication of TB difficult, described new insights into
the strategies used by M. tuberculosis to persist in macro-
phages, and discussed newly identified lipid effectors in viru-
lence. Since then, many additional mycobacterial genomes
have been sequenced, enhancing our understanding of myco-
bacterial evolution. More sophisticated genetic approaches
and new animal models have provided new and often surprising
insights into how the pathogenic mycobacteria survive and repli-
cate in macrophages and indeed orchestrate the formation of
granulomas, macrophage aggregates, and exploit them for their
expansion. We will discuss how the mechanisms used by myco-
bacteria to resist macrophages also render them drug tolerant,
a finding that has potential therapeutic implications. Finally, we
will discuss how mycobacteria paradoxically can benefit from
an over-exuberant host immune response to increase their
numbers further and be transmitted to a new, susceptible host.
The significance of these discoveries may be most fully appreci-
ated in the context of both mycobacterial evolution and host
adaptation. Where appropriate or interesting, we will compare
or contrast mycobacterial pathogenic strategies to those of
other pathogens. Many of our insights and ideas have come us-
ing Mycobacterium marinum, a close genetic relative of
M. tuberculosis (Stinear et al., 2008), which we have developed
as a valid and tractable model for M. tuberculosis pathogenesis
(Ramakrishnan, 2013; Tobin and Ramakrishnan, 2008). We will
therefore use M. marinum as a stand-in for M. tuberculosis, as
well as a comparator. We will organize our thoughts around
the ‘‘pathogenic personality’’ of M. tuberculosis and its many
facets as it goes through its pathogenic lifecycle—entry into
the host, attainment of a unique niche, multiplication within,
and exit from the host—all by avoiding, circumventing, or manip-
ulating host defenses with a unique ‘‘pathogenic signature’’ (Fal-
kow, 2008) (Figure 1).
Stealth Entry Affords Mycobacteria a Privileged Host
Niche
The optimal niche for a host-adapted pathogen within a host is
the environment in which the pathogen is readily able to repli-
cate. To arrive at and replicate in this niche, pathogens must
circumvent host defenses, (Falkow, 2006), which are in turn
substantially influenced by the commensal microflora that abun-
dantly populate our skin and mucosal surfaces. The host-
commensal alliance that forms the barrier to pathogens has
recently been reviewed in Cell, as part of this 40th anniversary
series (Belkaid and Hand, 2014).
M. tuberculosis is known to initiate infection most efficiently in
the lower lung through small aerosol droplets that contain only
one to three bacteria, a constraint that makes it less contagious
than respiratory pathogens, such as the group A streptococcus1498 Cell 159, December 18, 2014 ª2014 Elsevier Inc.and Corynebacterium diphtheriae that initiate infection in the
nasopharynx to cause, respectively (1) strep throat and scarlet
fever and (2) diphtheria, which are spread though large, wet
droplets. The insight that small droplets are most likely respon-
sible for transmitting TB comes from human epidemiological
studies examining transmission from index cases in confined
spaces (Bates et al., 1965; Houk, 1980). Corroborating the hu-
man studies are studies that track infection serially in rabbits,
demonstrating that aerosol droplet size negatively correlates
with infection burdens (Wells et al., 1948). When large aerosol-
ized particles containing 10,000 bacteria were administered,
they got stuck in the trachea and the rabbits got no or very little
infection. In contrast, upon receiving small aerosols containing
one to three bacteria that reached the alveolar spaces of the
lung, the rabbits all got progressive infection.
A teleological explanation for why TB initiates in the lower lung
at the cost of infectivity comes from the zebrafish larval model of
TB (Cambier et al., 2014). The zebrafish larva is optically trans-
parent so that infection with fluorescently labeled bacteria can
be monitored in exquisite detail (Takaki et al., 2013). To examine
the earliest interactions with the host, bacteria can be injected
into the hindbrain ventricle, a microbiologically sterile neuroepi-
thelium-lined cavity in which macrophages and neutrophils are
not present normally but migrate with the expected specificity
in response to the microinjection of specific chemokines or bac-
teria (Takaki et al., 2013; Yang et al., 2012). The zebrafish work
suggests that pathogenic mycobacteria have developed strate-
gies to avoid the microbicidal macrophages that are the default
recruits to keep mucosal commensal pathogens at bay. These
macrophages already primed to be microbicidal are recruited
through Toll-like receptor (TLR)-mediated signaling that is acti-
vated by the so-called pathogen-activated molecular patterns
(PAMPs) present on bacterial surfaces. In mouse and zebrafish
macrophages, the TLR-induced microbicidal activity is from
reactive nitrogen species produced by the action of inducible ni-
tric oxide synthase (iNOS) (Cambier et al., 2014); different micro-
bicidal effectors may be induced in human macrophages (Liu
et al., 2006). Mycobacteria, including M. tuberculosis and
M.marinum, are replete with PAMPs. Indeed, complete Freund’s
adjuvant that is used to prime immune responses is nothing but
an oil emulsion containing deadM. tuberculosis. However, these
mycobacteria express a surface lipid phthiocerol dimycoceros-
erate (PDIM) that masks the PAMPs so that they are not
‘‘seen’’ by the host innate immune system. Concomitantly,
they use a related surface lipid, phenolic glycolipid (PGL), to
induce the macrophage chemokine CCL2 to recruit and infect
macrophages that are growth-permissive for them. However,
this strategy of using a masking lipid to avoid the microbicidal
macrophages and a recruiting lipid to infect the permissive
ones would be ineffective in the upper airway, an environment
replete with an endless supply of TLR-stimulating commensal
bacteria. On this battlefield, mycobacteria would be collateral
damage caught in the crossfire; they would be killed by the mi-
crobicidal macrophages that are continually being recruited.
Hence the need for the third component of their tripartite immune
evasion strategy: small infection droplets that deliver them
directly into the alveolar spaces of the lower lung, which harbors
few, if any, commensals (Charlson et al., 2011) (Figure 2).
Figure 1. Pathogenic Life Cycle of M. tuberculosis
M. tuberculosis infection initiates when fine aerosol particles containing the bacteria coughed up by an individual with active disease are deposited in the lower
lungs of a new host. The bacteria recruit macrophages to the surface of the lung, which become infected, and serve to transport the bacteria across the lung
epithelium to deeper tissues. A new round of macrophage recruitment to the original infected macrophage is initiated, forming the granuloma, an organized
aggregate of differentiatedmacrophages and other immune cells. The granuloma in its early stages expands infection by allowing bacteria to spread to the newly
arriving macrophages. As adaptive immunity develops, the granuloma can restrict bacterial growth. However, under many circumstances, the infected gran-
uloma macrophages can undergo necrosis, forming a necrotic core that supports bacterial growth and transmission to the next host.There is a growing appreciation for a commensal-primed bar-
rier immunity that pathogens must evade, tolerate, or interrupt.
Helicobacter pylori, a commensal pathogen that famously
causes gastric ulcers, is also a heritage pathogen and has
adapted to survive in the stomach, where competition from
commensals is minimal (Monack, 2013). H. pylori too has
evolved to avoid detection via TLRs: its flagellin is not recog-
nized by TLR5 (Gewirtz et al., 2004), and its lipopolysaccharide
(LPS) has a lower affinity for TLR4 than that of other bacteria
(Moran, 2007). Therefore, like M. tuberculosis, H. pylori has
evolved to avoid proinflammatory host detection by initiating
infection in anatomical locations in which commensal competi-
tion is minimal. Although M. marinum and M. tuberculosis have
developed tactics to evade reactive nitrogen species,Mycobac-
terium avium that causes TB-like disease in birds appears to
have evolved a strategy to tolerate and even benefit from
them and, accordingly, does not express PDIM (Dhama et al.,
2011; Dumarey et al., 1994; Gomes et al., 1999; Onwueme
et al., 2005) (Figure 3). The case of host-adapted Salmonella,another macrophage-dwelling class of pathogens, may be illus-
trative as well. Salmonella infects via the terminal ileum that is
replete with colonizing bacteria. To facilitate its transit through
the commensal-laden gut, Salmonella appears to first drive an
inflammatory response that generates the reactive nitrogen
species to which the commensals are sensitive, but it, like
M. avium, is tolerant at least early during infection (Fang,
2004; Henard and Va´zquez-Torres, 2011). Upon reaching the
terminal ileum, the invading Salmonella enters into M cells,
specialized cells of the follicle-associated epithelium, a region
that is again relatively free from commensal competition (Jones
et al., 1994), and invades underlying macrophages. This multi-
pronged strategy to interrupt the commensal barrier so as to
reach the M cells affords Salmonella access to the systemic
phagocytes of the host (called the reticuloendothelial system).
The common theme emerging from these scenarios is that
host-adapted pathogens must develop strategies to circumvent
the host-beneficial commensal-primed immune barrier in order
to reach their replicative niche. We emphasize that, in turn,Cell 159, December 18, 2014 ª2014 Elsevier Inc. 1499
Figure 2. M. tuberculosis Evades Com-
mensal Bacteria to Infect Its Host
M. tuberculosis avoids the recruitment of micro-
bicidal macrophages to the site of infection by
masking its PAMPs with the PDIM lipid. A related
surface lipid PGL recruits permissive macro-
phages that can transport the bacteria into deeper
tissues. However, the upper airways are colonized
by resident microorganisms whose PAMPs recruit
microbicidal macrophages. Therefore, this myco-
bacterial strategy to evade microbicidal macro-
phages is only effective if infection is initiated in the
relatively sterile lower lung.commensals exert a selective pressure that has shaped path-
ogen evolution.
Mycobacteria have to engage with the host to become phago-
cytosed by permissive macrophages by simultaneously using
the surface lipid, PDIM, to dampen TLR signaling and by using
the related surface lipid, PGL, to induce CCL2 signaling. This
finding has additionally provided an understanding of the role
of these lipids in virulence (Siegrist and Bertozzi, 2014). PDIM is
expressed only by pathogenic mycobacteria, is absolutely
required for virulence, and is present in allM. tuberculosis clinical
isolates (Onwueme et al., 2005). Yet PDIM synthesis is metaboli-
cally costly so that it is readily lost in axenic culture (Kirksey
et al., 2011). PGL, in contrast, is not absolutely required for viru-
lence; it is not present in all clinical M. tuberculosis isolates
(Reed et al., 2004). However, it is present inmany of theW-Beijing
strains that have predominated in outbreaks in North America,
where TB is not prevalent. In the zebrafish, wherein low-dose in-
fections can be examined longitudinally from the first instances
of infection, PGL specifically increases infectivity of inocula of
one to three bacteria (that mimic those of human infection) by
enhancing the recruitment of mycobacterium-permissive macro-
phages. It is only in the context of examining the ability of the
pathogen to establish infection, rather than sustain it, that the
role of PGL is revealed. The presence of PGL on the bacterial1500 Cell 159, December 18, 2014 ª2014 Elsevier Inc.surface substantially increases the organ-
ism’s chances of reaching its preferred
replicative niche. These findings may also
serve to explain human studies showing
an association between TB susceptibility
and the high expression of CCL2, PGL’s
host partner in recruiting permissive mac-
rophages (Flores-Villanueva et al., 2005).
Further, the finding that PGL increases
virulence through enhanced infectivity
provides an understanding of why PGL is
present in M. cannetti strains, ancestral
to M. tuberculosis, as well as in
M. marinum, the closest genetic relative
of theM. tuberculosis complex (Onwueme
et al., 2005), suggesting its integral
role in the evolution of mycobacterial
pathogenicity. As noted before, TB is
generally thought to have infectedhumans
for 70,000 years, thus predating by
60,000 years the neolithic demographic transition and its resul-
tant crowding (Bos et al., 2014; Comas et al., 2013). Thus, PGL
may have been an essential virulence determinant for most of its
history. Perhaps, the greatly increased transmission opportunities
arising from human crowding made it dispensable.
Multiplication within the Host—The Macrophage Niche
The strategy elaborated by M. tuberculosis to traverse host
epithelial barriers within permissive macrophages is, of course,
predicated upon its ability to survive within these highly evolved
phagocytic host cells. Indeed, macrophages comprise the repli-
cative niche for most of the lifecycle, not only of M. tuberculosis
but of most other pathogenic mycobacteria (Figure 4). Accord-
ingly, the ability to replicate in host cells is a defining feature of
the pathogenic mycobacteria—be they human or animal patho-
gens—and reliably distinguishes them from their nonpathogenic
soil-dwelling cousins like Mycobacterium smegmatis (Shepard,
1957) (Figure 3). A clue for how this ability to grow in host mac-
rophages might have evolved comes from the remarkable
finding that the ability of mycobacteria to replicate in macro-
phages tracks completely with their ability to grow in unicellular
free-living amebae. Pathogenic mycobacterial species can repli-
cate in amoebae, whereas M. smegmatis cannot (Cirillo et al.,
1997). Moreover, to the extent tested, the same mycobacterial
Figure 3. An Evolutionary Perspective of Mycobacterial Pathogenicity
An analysis of the pathogenic traits and preferred hosts of diverse mycobacterial species in relation to their genomes.determinants are required for growth in macrophages and
amoebae (Alibaud et al., 2011; Hagedorn et al., 2009; Hagedorn
and Soldati, 2007; Solomon et al., 2003). Thus, predatory envi-
ronmental amoebae may have served as the ancient evolu-
tionary training ground for mycobacterial pathogens to survive
in the macrophages of their multicellular hosts. This has been
postulated for Legionella, an accidental human pathogen that
can cause serious pneumonia after being aerosolized from
potable water sources where it is thought to be sustained
through replication in environmental amoebae (Fields et al.,
2002).
Any foreign particulate that is phagocytosed by macrophages
is destined to be processed through the endocytic pathways.
Thus, intracellular pathogens have evolved diverse ingenious
signature strategies to thwart, modulate, exploit, or avoid host
endocytic pathways. Broadly speaking, these pathogens can
resist lysosomal fusion to reside in non-acidified endosome-
like compartments, survive (or even require) acidification so as
to be able to reside in acidified lysosome-like compartments,
or break out of the phagosome altogether to reside in the cytosol
(Alix et al., 2011) (Figure 4). Most experimental studies on the
virulence of intracellular mycobacteria have been conducted
using either mouse or human cultured macrophages. For
M. tuberculosis, observations in cultured macrophages have
produced disparate results probably because the cell lines, cul-
ture conditions, and kinetics of infection differ considerably be-
tween different laboratories. M. tuberculosis is reportedly found
localized to non-acidified early endosomes or found in acidified
lysosomes with a small proportion of the bacteria eventually
breaking out of the phagosome to reside in the cytosol (Cosma
et al., 2003; van der Wel et al., 2007). Indeed, mycobacteriahave specific virulence determinants that promote, at least in
cultured cells, both the avoidance of acidification as well as
acid resistance, suggesting that, despite their best attempts,
they might find themselves in acidified compartments (Rohde
et al., 2007). In addition, the ability to break out into the cytosol
is dependent on a specialized bacterial secretion system,
ESX-1 (van der Wel et al., 2007), whose role we will elaborate
upon in the context of the tuberculous granuloma in the following
section.
The multiple subcellular compartments that M. tuberculosis
can occupy within macrophages speak to the plethora of
defenses with which theymust contend even in themost permis-
sive of macrophages. It is hardly surprising that diverse myco-
bacterial determinants are required for macrophage survival
(Forrellad et al., 2013). What is surprising is that the obvious
prediction that these determinants were acquired during myco-
bacterium’s jump to becoming an amoeba dweller does not
stand scrutiny. Although our search was not exhaustive, virtually
all of the important M. tuberculosis virulence determinants that
specifically promote intracellular growth are present in
M. smegmatis (Forrellad et al., 2013)! What is more, in the cases
tested, the M. smegmatis gene can substitute for its
M. tuberculosis gene in mediating macrophage growth and viru-
lence, suggesting that no or few further modifications were
needed to confer this function (Houben et al., 2009). For
instance, the eukaryotic-like serine-threonine protein kinase
PknG is secreted into the phagosomal lumen and promotes
macrophage growth by inhibiting lysosomal fusion and thereby
acidification of the mycobacterial phagosome (Walburger
et al., 2004). Although the M. smegmatis PknG homolog is able
to restore macrophage growth of the M. tuberculosis pknGCell 159, December 18, 2014 ª2014 Elsevier Inc. 1501
Figure 4. Intracellular Niches ofM. tubercu-
losis
The observed intracellular niches of
M. tuberculosis within macrophages are shown
with other pathogens occupying those niches
also listed. Confirmed trafficking pathways are
indicated with continuous arrows and putative
ones with dashed arrows. Pathways dependent
on the mycobacterial ESX1 secretion system are
indicated.mutant, its function in the context of this saprophytic organ-
ism remains unknown. PknG is translationally repressed in
M. smegmatis at least under axenic growth, suggesting that
there is some specific ‘‘real-life’’ situation during life in the soil
when it is induced, presumably to perform some specific func-
tion (Houben et al., 2009).
Perhaps the most fascinating example of conservation
across mycobacteria is that of the mycobacterial energy-
dependent efflux pumps, which we recently discovered to be
M. tuberculosis macrophage growth factors by a circuitous
route when looking for the basis of antibiotic tolerance (Adams
et al., 2011; Rengarajan et al., 2005; Szumowski et al., 2013). In
addition to developing genetic drug resistance through fixed
mutations, M. tuberculosis famously develops what is called
‘‘phenotypic drug resistance’’ or ‘‘drug tolerance,’’ wherein it
becomes transiently resistant to antibiotics (in the absence of
fixed genetic mutations) in the host. This necessitates long
treatment periods to achieve clinical cures (Connolly et al.,
2007). Mycobacterial drug tolerance has long been attributed
to the bacteria being in a non-replicating or dormant state in
the host (Chao and Rubin, 2010; Rittershaus et al., 2013). How-
ever, our recent work shows that, when M. tuberculosis enters
macrophages, it is, in fact, the actively replicating bacteria
within the macrophages that develop antibiotic tolerance
through the induction of specific macrophage-induced efflux
pumps (Adams et al., 2011; Schnappinger et al., 2003). These
same efflux pumps that mediate macrophage-induced drug
tolerance also promote intracellular mycobacterial growth
(Adams et al., 2011; Schnappinger et al., 2003). This suggests
that these pumps may have evolved in the soil dwellers to
defend against environmental toxins and inhibitors (including
naturally occurring antibiotics) but came to be useful for the
contemporary lifestyle of the pathogenic mycobacteria, facili-
tating intracellular survival, perhaps by protecting them against
the antimicrobial peptides in macrophages. With the advent of
chemotherapy, their ancestral function to defend against antibi-
otics or other growth inhibitors affords added benefit in surviv-
ing within the host; the same pumps may efflux the natural
macrophage defenses as well as the administered antibiotics
(Adams et al., 2011; Schnappinger et al., 2003). These findings
additionally have therapeutic implications because efflux pump1502 Cell 159, December 18, 2014 ª2014 Elsevier Inc.inhibitors should prevent the replication
of intracellular M. tuberculosis. More-
over, combining efflux pump inhibitors
with standard antibiotic therapy should
be a ‘‘double whammy’’ to intracellular
M. tuberculosis because they shouldinhibit intracellular growth in their own right and additionally
allow the antibiotics to kill these bacteria better by preventing
their efflux. Indeed, we have found this to be the case using
inexpensive, well-tolerated approved human drugs that are
currently used for other purposes (e.g., verapamil) (Adams
et al., 2011, 2014). Moreover, the addition of verapamil to stan-
dard antituberculous chemotherapy reduces relapse rates in
M. tuberculosis-infected mice (Gupta et al., 2013). On the basis
of all these findings, clinical trials of verapamil as a TB treat-
ment-shortening agent are imminent.
In summary, returning to our comparative theme, it would
appear that the environmental mycobacteria, e.g., M. smegma-
tis, had determinants that allowed them to survive in the soil
even though they could not survive within unicellular predators.
The selection for the ability to survive within unicellular
amoebae and eons later within the macrophages of multicel-
lular creatures required using these determinants together
with acquiring new as yet unknown ones, possibly by horizon-
tal gene transfer (Figure 4). One could argue that mycobacteria
come ‘‘pre-loaded’’ with the means to survive within a profes-
sional phagocytic cell. It is perhaps a general strategy for other
soil organisms adapting to animal hosts as illustrated as well
for Rhodococcus equi, the horse and occasional human path-
ogen that diversified from soil-dwelling Rhodococci (Letek
et al., 2010). In the case of mycobacteria, the pathogenic
forbearer selected for growth in amoeba appears to have
then followed different evolutionary branches to dwell in
different hosts, sometimes involving the acquisition of plasmids
and, as is so often the case, gene loss, so as to fine-tune adap-
tation to specific hosts (Boritsch et al., 2014; Wang and Behr,
2014) (Figure 3).
In the following section, we will discuss the elaborate macro-
phage manipulation strategies used by M. tuberculosis to form
the granuloma—the hallmark pathological structure of TB. We
argue that it is as much a mycobacterial strategy for survival as
it is a host defense response.
Multiplication in the Host—Exploiting the Granuloma
A granuloma is fundamentally an organized aggregate of macro-
phages whose membranes become tightly interdigitated like
those of epithelial cells, leading them to be called epithelioid cells
Figure 5. Mycobacteria Exploit the Granuloma to Expand Their
Numbers in Early Infection
Mycobacteria within infected macrophages induce in an ESX1-dependent
fashion MMP9 expression in epithelial cells surrounding the nascent granu-
loma. MMP9 stimulates the recruitment of new macrophages to the granu-
loma.Multiple new arrivals phagocytose the bacterial contents of a given dying
infected macrophage, thus spreading the bacteria to new macrophages and
providing them new expansion niches.(Adams, 1976; Bouley et al., 2001). Granulomas can form in
response to any number of persistent stimuli, both infectious
and noninfectious, so that they are associated with myriad dis-
eases (Ramakrishnan, 2012). They were first recognized as
distinct structural entities in the context of human TB in the
17th century, preceding by some 200 years the discovery of
M. tuberculosis as its cause, and even today, TB remains the
most common cause of granulomas worldwide (Ramakrishnan,
2012). For a very long time, the tuberculous granuloma has
been held to be an essential host protective structure—a fortress
containing a complex mixture of diverse host cells that walls off
bacteria (Saunders and Cooper, 2000) (Chao and Rubin, 2010;
Rittershaus et al., 2013). Indeed, clinical and epidemiological
studies clearly support the idea that the granuloma can sterilize
infection in many cases (Cosma et al., 2004; Feldman and Bag-
genstoss, 1938). Yet, we argue that there is an inextricable link
between highly organized granulomas and heavy bacterial bur-
dens in TB, suggesting that, in many cases, the granuloma can
be at least conducive to high bacterial burdens if not downright
supportive of them (Connolly et al., 2007). Indeed, our findings
over the last decade suggest that mycobacteria actually
enhance the formation of granulomas and have adapted toexploit these structures for their expansion and dissemination
(Davis and Ramakrishnan, 2009). This modified view of the gran-
ulomawasmade possible by studies in the zebrafish in which we
could visualize the earliest events of granuloma formation
around the first infected macrophage that had arrived in the
deep tissues. Bacterial expansion in granulomas is accom-
plished by the spread of bacteria from dying macrophages to
newly arriving ones (Davis and Ramakrishnan, 2009). When
mycobacterial numbers increase to a certain threshold in individ-
ual macrophages, they undergo an apoptotic death that leaves
viable bacteria still encased within the dead cells (Figure 5).
Concomitantly, multiple new uninfected macrophages are re-
cruited to the nascent granuloma that engulf the bacterial con-
tents of a given dead or dying macrophage, thus enabling
them to fill up the new cells. This process of macrophage death
and re-phagocytosis enables a tremendous expansion of the
bacterial niche, all within macrophages (Davis and Ramak-
rishnan, 2009).
At a molecular level, this coordinated macrophage death and
re-phagocytosis is mediated through a specialized mycobacte-
rial secretion system called ESX-1, most likely through its
secreted effector ESAT6 (Davis and Ramakrishnan, 2009; Volk-
man et al., 2004; Volkman et al., 2010) (Figure 5). ESAT6 has
been shown to induce apoptosis of infected cells in culture
through multiple pathways, one or more of which may be oper-
ant in the granuloma (Choi et al., 2010; Derrick and Morris, 2007;
Keane et al., 1997; Mishra et al., 2010; Swaim et al., 2006). ESX-
1/ESAT-6 also recruits macrophages by inducing host matrix
metalloproteinase 9 (MMP9) in epithelial cells surrounding the
nascent granuloma (Volkman et al., 2010). If host MMP9 function
is decreased, infection is attenuated, with reduced granuloma
formation (Volkman et al., 2010). These discoveries, initially
made in the zebrafish, are corroborated by findings in human
TB showing that MMP9 is induced in epithelial cells surrounding
lung granulomas, and increased MMP9 secretion is associated
with increased severity and mortality in tuberculous meningitis
(Elkington et al., 2007; Price et al., 2001).
In summary, M. tuberculosis appears to use at least two
distinct pathways to recruit macrophages. WhenM. tuberculosis
first enters the host animal, it uses its PGL surface lipid to recruit
macrophages through host CCL2, which then bring the myco-
bacteria across host epithelium to deeper tissues (Cambier
et al., 2014) (Figure 2). The intracellular bacteria then orchestrate
the recruitment of additional macrophages to form the granu-
loma through their ESX-1 locus (Figure 5). Why the bacteria tran-
sition from using PGL to using ESAT6 to drive macrophage
recruitment is unclear. What is clear is that, in both phases,
macrophage recruitment benefits the mycobacteria as much
as the host! Thus, CCL2 andMMP9may both represent host de-
terminants that have been co-opted by mycobacteria for their
benefit, and increased CCL2 and MMP9 expression are both
linked to human susceptibility to TB (Elkington et al., 2007; Price
et al., 2001; Flores-Villanueva et al., 2005).
It is curious that, although the growing granuloma supports
M. tuberculosis expansion, the macrophages within this struc-
ture generally become more microbicidal suggesting that the
bacterium should be put at a further disadvantage (Adams,
1976; Bouley et al., 2001). But it appears that the mycobacteria,Cell 159, December 18, 2014 ª2014 Elsevier Inc. 1503
in turn, rapidly adapt to themore hostile environment in the gran-
uloma by transcriptionally inducing new genes (e.g., efflux
pumps) upon entering a macrophage, which aid in intracellular
survival. Moreover, when an infected macrophage forms or joins
a granuloma, its intracellular bacteria rapidly induce additional
genes that help it to counter the additional stresses of living
within the cellular environment of the granuloma (Cosma et al.,
2004; Davis et al., 2002; Ramakrishnan et al., 2000). If an infected
animal with mature granulomas (frogs or zebrafish with
M. marinum, or mice with M. tuberculosis) is superinfected
with new mycobacteria, these bacteria enter new macrophages
that preferentially migrate to existing granulomas rather than
avoiding them as hostile sites (Cosma et al., 2004, 2008). It is
as if mycobacteria ‘‘know’’ that, although the granuloma may
not be a place where ‘‘the living is easy,’’ it still does afford
them a preferred and, paradoxically, a protected multiplication
niche and, aswe shall see in the following section, a transmission
niche as well.
Our proposed mycobacterial-centric view of granuloma
biology and function returns us yet again to questions about
how mycobacteria evolved to pathogenicity. We focus now on
the ESX-1 secretion system and its effector, ESAT6. ESX-1/
ESAT6, like most other M. tuberculosis virulence factors, is
also present in M. smegmatis. However, in M. smegmatis, this
secretion system regulates bacterial conjugation (Coros et al.,
2008; Parsons et al., 1998) (Figure 3). The M. tuberculosis and
M. smegmatis homologs are functionally conserved (Converse
and Cox, 2005; Flint et al., 2004), but the co-option of bacterial
gene-exchange systems for virulence is not special to mycobac-
teria. In diverse bacterial pathogens likeH. pylori, Legionella, and
Agrobacterium, the type IV secretion system that is required for
virulence also mediates DNA transfer or uptake. Equally inter-
esting is the finding that ESX is not evenmycobacterium specific;
an ESX homolog mediates virulence in R. equi while also being
present in the soil Rhodococci and, indeed, being widely distrib-
uted in GC-rich soil bacteria (Letek et al., 2010). The mechanistic
details of how ESX-1/ESAT6 mediates granuloma formation and
virulence remain to be understood. ESAT6 is reported to be
associated with the ability of M. tuberculosis subpopulations to
break out of the phagosome (De Leon et al., 2012; Hsu et al.,
2003; van der Wel et al., 2007) (Figure 4). In fact, prior to full-
fledged phagosomal rupture, ESAT6 may permeabilize the
phagosomal membrane enough to expose mycobacterial DNA
to the host cytosolic DNA-sensing pathway (Manzanillo et al.,
2012). This results in the induction of type I interferon, a cytokine
that is best known for its antiviral activity; however, mycobacte-
ria appear to drive this cytosolic DNA-sensing response in their
favor. Components of the cytosolic pathway and type I interferon
mediate host susceptibility in animal models. Type I interferon re-
ceptor knockout mice are more protected against TB, similar to
the protection against TB afforded by knocking out MMP9 (Man-
zanillo et al., 2012; Mayer-Barber et al., 2014; Taylor et al., 2006;
Watson et al., 2012). In humans too, a type I IFN transcriptional
signature has been associated with active versus subclinical
TB, suggesting it is a host susceptibility factor for disease pro-
gression (Berry et al., 2010). Whether ESAT6 modulates host
MMP9 activity and granuloma formation through its membrane
permeabilization activity and/or by triggering the cytosolic DNA1504 Cell 159, December 18, 2014 ª2014 Elsevier Inc.detection system still remains unclear. What is clear is that it rep-
resents another fascinating case in which a ubiquitous bacterial
determinant has been co-opted and fine-tuned through genetic
selection—not just to modulate bacterial growth in macro-
phages, but also to become integrated with other bacterial
genes for a choreographed manipulation of macrophage migra-
tion and death to build the granuloma.
Of course, this initial phase of bacterial expansion in the gran-
uloma is followed by the advent of an adaptive immune response
that can often eradicate the tubercle bacilli, presumably by
increasing the microbicidal capacity of the granuloma macro-
phages (Ramakrishnan, 2012). Epidemiological evidence would
suggest that, with a little help from adaptive immunity, the gran-
uloma can sterilize infection in most cases (Cosma et al., 2004;
Feldman and Baggenstoss, 1938). Conversely, the very large
number of active TB cases with full-fledged mature granulomas
that are replete with lymphocytes suggests that mycobacteria
have evolved additional strategies to evade adaptive immunity.
As we have detailed in prior reviews, many of these strategies
have been elucidated recently and include delaying both T cell
priming in the lymph nodes and their arrival and activity in the
granuloma (Pagan and Ramakrishnan, 2014; Ramakrishnan,
2012). Thus, M. tuberculosis reduces macrophage responsive-
ness to signaling by g interferon, the main T cell cytokine (Ba-
naiee et al., 2006). Finally, M. tuberculosis can synthesize its
own tryptophan so that, unlike some other intracellular patho-
gens (e.g., Chlamydia), it is able to survive the intracellular tryp-
tophan starvation brought on by g interferon (Zhang et al., 2013).
Thus, bacterial interactions with the host adaptive immune sys-
tem add layers of complexity to the host-pathogen interface.
The tubercle bacillus first induces an innate inflammatory
response to accelerate macrophage responses (recruitment,
phagocytosis, apoptosis) that are normally protective to turn
the granuloma response into a bacterial production factory. By
then delaying T cell priming, arrival, and activation together
withmacrophage responsiveness bywhat appears to be a highly
orchestrated strategy, the bacteria buy themselves yet more
time to establish a strong replicative niche in the granuloma.
Many diverse microorganisms induce granulomas, and it
will be interesting to compare the pathways and consequences
of granuloma formation for each of them. Within the myco-
bacteria, a tantalizing difference in granuloma formation path-
ways is already apparent by comparing M. marinum and
M. tuberculosis to M. avium (Figure 3). ESAT6/ESX1 is absent
from M. avium, which is not a particularly successful pathogen
in human hosts (Dhama et al., 2011; Dumarey et al., 1994;
Gomes et al., 1999; Onwueme et al., 2005; Sørensen et al.,
1995) (Figure 3). However, in birds,M. avium causes a full-blown
granulomatous disease that is transmissible, usually by inges-
tion. So M. avium granulomas must form through a different
pathway. Meanwhile, M. tuberculosis ESAT6 has been recently
revealed to have yet another function in supporting bacterial
expansion in the granuloma—it induces immunosuppressive
regulatory T cell populations that delay the migration of effector
T cells into the granuloma (Shafiani et al., 2013; Shafiani et al.,
2010). Thus, ESAT6 may prolong the phase of bacterial expan-
sion in the innate granuloma that it orchestrates in the first place
(Davis and Ramakrishnan, 2009). In this context, it is intriguing
that birds, in contrast to mammals and zebrafish, appear to have
lost the transcription factor FoxP3 that is required for regulatory
T cell development (Andersen et al., 2012). Therefore, a plausible
explanation for M. avium’s loss of ESX-1/ESAT6 is that it is su-
perfluous for granuloma expansion in its bird hosts. In contrast,
its retention in M. tuberculosis and M. marinum may reflect its
central role in granuloma expansion in mammalian and fish
hosts. The selective forces of the host’s immune system are re-
flected in the array of expressed virulence genes seen in each
host-adapted mycobacterial species. Although our conjecture
on the evolutionary connections may well be incorrect, our
revised view of the role of the granuloma in the pathogenesis
of tuberculosis can be tested further experimentally and may
have potential clinical relevance. We predict that the reduction
of granuloma formation by pharmacological inhibition of the rele-
vant host pathways (e.g., MMP9) should ameliorate infection.
Exit from the Host—Escaping the Granuloma
A host-adapted pathogen’s final step to ensure its evolutionary
success is to exit the host and enter a new host for the infection
cycle to start anew. In the case ofM. tuberculosis, it must exit the
granuloma of its infected host to enter and establish infection in a
new host. Epidemiological evidence suggests that transmission
occurs most efficiently from individuals with organized granu-
lomas that have undergone central necrosis (Sharma et al.,
2005; Reichler et al., 2002; Bekker and Wood, 2010; Huang
et al., 2014). The necrotic areas rupture into the bronchial tree,
thus exposing the mycobacteria to the airway whence they can
be aerosolized in cough droplets. Recent work fromboth our lab-
oratory and others takes a slightly modified view of the dynamics
of cell death in a granuloma (Ramakrishnan, 2012). Broadly
speaking, infected granuloma macrophages can die in two
ways: by apoptosis or by necrosis. Apoptosis leaves the host
cell membranes intact so that the bacteria remain encasedwithin
the macrophage corpse and are readily phagocytosed by new
entering cells. In contrast, macrophage necrosis, or lysis, re-
leases the intact bacteria into the extracellular milieu. This
necrotic debris, or caseum, seems to be an ideal bacterial
growth medium as the multiplying bacteria reach much higher
numbers extracellularly and grow in characteristic serpentine
cords. Thus, in our view, apoptotic death favors bacterial expan-
sion or maintenance of the granuloma by providing new cells to
grow in, albeit still restricted by macrophage defenses. Bacterial
lysis from the macrophages allows more exuberant growth, re-
flecting the ineffectiveness of extracellular host defenses against
mycobacteria. Moreover, recent work suggests that these
corded extracellular mycobacteria are not readily engulfed by
new macrophages the way that bacteria within apoptotic cells
are (Bernut et al., 2014). It is not fully understood how the dy-
namics of the granuloma shift to favor necrosis, but some inter-
esting insights are emerging.
Our studies inM. marinum-infected zebrafish have uncovered
two pathways that lead to macrophage necrosis, each through
opposite dysregulation of TNF, resulting in too little or too
much TNF. TNF is required for macrophagemicrobicidal activity,
although we do not understand the specific mechanisms and ef-
fectors (Clay et al., 2008). Whereas host TNF deficiency causes
mycobacteria to grow exuberantly withinmacrophages that thendie and release them to the extracellular milieu (Clay et al., 2008),
we have found that an excess of host TNF causes infected mac-
rophages to undergo necrosis, through a programmed pathway
called necroptosis (Roca and Ramakrishnan, 2013; Tobin et al.,
2012). Host TNF excess causes the activation of the RIP1 and
RIP3 kinases that then, through a series of steps, induce reactive
oxygen species in the macrophage mitochondria (Roca and
Ramakrishnan, 2013; Tobin et al., 2012). Reactive oxygen has
dual effects: it kills both mycobacteria and macrophage. The
net result is that, just as the macrophage is on its way to killing
its infecting mycobacteria, it dies. The few surviving mycobacte-
ria that are released extracellularly can expand their numbers
rapidly.
Perturbation of several pathways could lead to TNF dysregula-
tion and, in turn, granuloma necrosis. One that we identified in a
zebrafishmutant screen for susceptibility toM.marinum involves
dysregulation of the leukotriene A4 hydrolase (LTA4H), a syn-
thetic enzyme in the eicosanoid pathway that catalyzes the
synthesis of thehighly proinflammatory lipid leukotrieneB4 (Tobin
et al., 2010, 2012). LTA4H deficiency prevents the synthesis of
this leukotriene and instead causes the accumulation of the
anti-inflammatory lipid lipoxin A4, which represses the TNF
response. In contrast, LTA4H excess causes an overproduction
of leukotriene B4 and an excess of TNF. In humans, a common
LTA4H promoter variant regulates gene expression and homozy-
gotes for both the low- and high-expression variants that are
associated with low and high inflammation, respectively. Individ-
uals with low- and high-expression variants of LTA4H get severe
tuberculousmeningitis, with a highmortality. In contrast, the het-
erozygotes, with an intermediate (presumably optimal) level of
LTA4H expression, are protected. These findings, in turn, have
therapeutic implications—in a Vietnamese tuberculous meningi-
tis cohort, adjunctive treatment with the broadly immunosup-
pressive glucocorticoids, which are now routinely administered
along with antitubercular chemotherapy, only prevented mortal-
ity of the high LTA4H group while possibly increasing mortality of
the low LTA4H individuals (Tobin et al., 2012; Tobin et al., 2010).
These results suggest that patient genotype-directed glucocorti-
coid treatment may optimize TB treatment.
Our detailed understanding of the two pathways through
which excess TNF-induced mitochondrial reactive oxygen
causes macrophage necrosis also suggests new approaches
to TB therapy (Roca and Ramakrishnan, 2013; Tobin et al.,
2012). Reactive oxygen causes the translocation of the matrix
mitochondrial protein cyclophilin D to participate in the formation
of a pore on the mitochondrial membrane, thus causing leakage
of mitochondrial contents. Additionally, the reactive oxygen also
causes overproduction of a cellular lipid called ceramide that in-
duces necrosis through mechanisms that are not yet clear. We
have identified currently available oral drugs that can block
each of these pathways. Alisporivir, a drug in phase 3 clinical tri-
als for another disease, blocks cyclophilin D, and desipramine, a
tricyclic antidepressant, inhibits ceramide production. In the ze-
brafish, the combined use of these drugs allows the reactive ox-
ygen to kill the bacteria without killing the macrophages and
thereby converts the hypersusceptible state of TNF excess to
hyperresistant. It is possible that these drugs will have a similar
effect in humans who induce excess TNF during infection.Cell 159, December 18, 2014 ª2014 Elsevier Inc. 1505
Necrosis from excessive TNF may be further exacerbated by
the participation of adaptive immunity, as much of the TNF
induced in TB is produced by T cells (Roach et al., 2002; Saun-
ders et al., 2004). Perhaps M. tuberculosis has co-opted
T cells into producing the TNF that causes macrophage necrosis
and thus encourages transmission. Indeed, T cell epitopes of all
known mycobacterial T cell antigens are reported to be hyper-
conserved across strains globally, even more so than those of
essential genes (Comas et al., 2010). This finding suggests that
T cell recognition favors the survival and transmission of myco-
bacteria, arguably by inducing TNF-mediated necrosis as
described above. The hyperconservation of T cell epitope re-
gions of expressed mycobacterial antigens highlights the close
evolutionary relationship between T cell recognition and bacte-
rial fitness. Epidemiological evidence suggests that individuals
with diminished adaptive immunity (e.g., HIV-infected individuals
or children) tend to have smaller and less necrotic granulomas
than immunocompetent adults, and these former individuals—
though more susceptible to TB—do not transmit it as well as
the latter (Huang et al., 2014). Globally, >80%of active TB occurs
in individuals who are not HIV infected (Zumla et al., 2013). This
link between disease and an intact host adaptive immune sys-
tem may suggest thatM. tuberculosis takes advantage of adap-
tive immunity for its transmission.
In summary, our view is that M. tuberculosis and many other
pathogenic mycobacteria are not innocent bystanders during
the formation of granuloma. They can modulate the host
response to infection to build and modify this complex immuno-
logical entity into a niche that can sustain infection, first through
intracellular growth and then through extracellular growth that
also favors transmission.
Concluding Thoughts
The case of M. tuberculosis exemplifies how a series of genetic
adaptations can convert a soil-dwelling microbe into one of the
most successful andenduringpathogensof humanity.Morepeo-
ple are thought to have died of TB than of any other infectious dis-
ease throughout history, andmorepeople are afflictedwith active
TB disease today than at any other time in history (Lawn and
Zumla, 2011). While marveling at the exquisite bacterial adapta-
tions that have honed this microbe’s success in its human niche,
it is important to remember that most infected individuals (classi-
cally reported to be 90%) can successfully contain or clear the
infection (Zumla et al., 2013). This occurs either through an initial
mobilization of innate immune mechanisms or, failing that,
through adaptive immunity. In this Review, we have tried to point
out how the outcome of each step of the host-pathogen interac-
tion can represent ‘‘success’’ for the host—infection can be sup-
pressed or cleared at the first site of infection, in the innate gran-
uloma, or later, when the granuloma is further re-enforced by
adaptive immunity (Cambier et al., 2014; Lin et al., 2014; Adams
et al., 2011; Rengarajan et al., 2005; Szumowski et al., 2013).
Suppression of infection can result in a clinical latency during
which the bacteria persist indefinitely in the host and can pro-
duce active disease even decades later—a scenario that is
emphasized in the literature (Chao and Rubin, 2010; Cosma
et al., 2003; Rittershaus et al., 2013). However, careful longitudi-
nal studies from the pre-antibiotic era suggest that most1506 Cell 159, December 18, 2014 ª2014 Elsevier Inc.contemporary human disease manifests within a few months
of infection or is cleared (Cosma et al., 2003). In today’s world,
it is these relatively recently infected individuals who transmit
the bulk of the disease, rather than those in whom disease has
recrudesced after many decades. From a medical perspective,
this places the impetus on understanding how the majority of in-
fected individuals progress to disease relatively rapidly. How-
ever, it is likely that clinical latency played an important role in
sustaining the organism through the 60,000 years before TB
became a ‘‘crowd’’ disease. The organism early on in its evolu-
tion did not have the advantage of large susceptible populations
that resulted from the Neolithic revolution of domestication and
the development of agriculture. It is hard to imagine how the early
hunter-gathers living in small groups could have sustained
M. tuberculosis without the benefit of activation of transmissible
disease in previously healthy infected individuals who were able
to travel long distances. We speculate that, in the latter part of its
history, TB has shifted from being a heritage disease to a crowd
disease, and the opportunities afforded by a growing susceptible
host populationmay have led not only to increased transmission,
but also to a more aggressive stance against innate immune de-
fenses, leading to epidemic spread rather than persistence.
It is interesting in this context that wemay be witnessing a shift
in transmission of another major mycobacterial disease leprosy.
Leprosy is caused by Mycobacterium leprae, which appears to
have also evolved from the common M. tuberculosis-M. mari-
num ancestor (Figure 3). M. leprae is particularly intriguing
because it has undergone substantial gene reduction to the point
where it has lost its capacity for axenic growth (Cole et al., 2001).
At the same time, it has become specialized in its pathogenic
niche, infecting Schwann cells of the peripheral nervous system
through complex mechanisms (Masaki et al., 2013). For most of
its pathogenic human history,M. leprae has been a strict human
pathogen, with transmission occurring only through prolonged
contact with infected humans. Yet, in very recent times, the
nine banded armadillo in the Southeastern United States
became infected from humans and has now become a full-
fledged reservoir for disease, so that leprosy is now mainly a zo-
onotic disease in this area (Truman et al., 2011). Albeit in a less
dramatic way, M. tuberculosis must clearly have made adapta-
tions to the very great changes in human lifestyles to retain its
success. Understanding these changes may have more than ac-
ademic value; it may help us better understand the disease itself
and hence its treatment. The parallel evolution of pathogens to
keep up with changing environments is hardly unique to myco-
bacteria but is shared with many, many other pathogens.
Finally, our recent work has repeatedly confronted us with the
fact that TB is not as much a disease of failed immunity as it is of
coevolution. At every step of infection, the bacterium appears to
be inducing and benefitting from an over-exuberant response
using the very inflammatory pathways that are thought to have
evolved to thwart bacteria—CCL2 induction to enter the host,
MMP9 induction to expand in the granuloma, and finally TNF
and T lymphocytes to exit the granuloma for transmission.
Despite all of this, both host and pathogen have prevailed.
That is why we consider M. tuberculosis to be a paradigm of a
host-adapted microorganism. It has coevolved with the human
immune system, discarding and gaining genes to be in tune
with it. As an ancient disease agent adapting to humans, the
microbe could not have anticipated that humans would be so
successful. Yet its stealth and subtlety have allowed it to thrive
even in the face of modern medicine. While new therapeutic av-
enues will most likely be found, we must not undervalue the po-
wer of genetic selection for the survival of any microorganism—
and, based on past performance, particularly forM. tuberculosis.
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